EMEA-000084-PIP02-10 - paediatric investigation plan

Rizatriptan

Key facts

• Invented name:
  Maxalt and associated names
• Active Substance:
  Rizatriptan
• Therapeutic area:
  Pain
• Decision number:
  P/27/2011
• PIP number:
  EMEA-000084-PIP02-10
• Pharmaceutical form(s):
  Tablet
• Condition(s) / indication(s):
  Treatment of migraine
• Route(s) of administration:
  Oral use
• Decision type:
  P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
• Decision date:
  28/01/2011
• Compliance procedure number:
  EMEA-C-000084-PIP02-10
• Compliance opinion date:
  14/09/2011
• Compliance outcome:
  Positive

Decision

P/27/2011: EMA decision of the 28 January 2011on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for rizatriptan benzoate (Maxalt and associated names), ...

AdoptedReference Number: EMA/37992/2011